Stephen Thein
YOU?
Author Swipe
View article: Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia Open
Background The earliest recognized biomarker of AD is deposition of Aβ amyloid that leads to formation of plaques and may, over time, trigger or at least be followed by gliosis/neuroinflammation and neurofibrillary tangles, accompanied by …
View article: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial Open
Rationale: Obstructive sleep apnea (OSA) is a common sleep disorder for which the principal treatment option, continuous positive airway pressure, is often poorly tolerated. There is currently no approved pharmacotherapy for OSA. Ho…
View article: Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet Open
The Lauriet study is registered on ClinicalTrials.gov, NCT03828747, and EudraCT 2018-003398-87.
View article: 0538 Mariposa: Oral Therapy AD109 Improves Objective & Patient Reported Outcomes In OSA. Randomized, Placebo Controlled Clinical Trial
0538 Mariposa: Oral Therapy AD109 Improves Objective & Patient Reported Outcomes In OSA. Randomized, Placebo Controlled Clinical Trial Open
Introduction Obstructive sleep apnea (OSA) is a common disorder with often poorly tolerated treatment . While there is currently no approved pharmacotherapy for OSA, the combination of noradrenergic and antimuscarinic drugs, counteracting …
View article: Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder Open
ClinicalTrials.gov (NCT03679884) [first posted: 21 September, 2018], https://clinicaltrials.gov/ct2/show/NCT03679884 .
View article: Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA
Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA Open
View article: Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial
Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial Open
This study provides preliminary evidence of the potential utility of lemborexant as a treatment to address both nighttime and daytime symptoms in patients with ISWRD and AD-D.
View article: A Randomized, Double Blind, Vehicle Controlled, Parallel, Phase Ii Study to Evaluate Efficacy and Safety of Bac in Patients With Alzheimer’s Disease or Vascular Dementia
A Randomized, Double Blind, Vehicle Controlled, Parallel, Phase Ii Study to Evaluate Efficacy and Safety of Bac in Patients With Alzheimer’s Disease or Vascular Dementia Open
Background: Dementia causes a long-term and gradual cognitive decline and there is no treatment to slow or stop the progression of dementia. Methods: Middle cerebral artery occlusion in rats was employed to investigate the effects of BAC i…
View article: Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial
Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial Open
Rationale: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness.Objectives: To assess treatment effects of solriamfetol, a dopamine/norepinephrine reuptake inh…
View article: Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial Open
Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently avail…
View article: [P4–403]: EVALUATION OF RAPID, ON‐SITE APOE GENETIC TESTING FOR SUBJECT OUTREACH AND RECRUITMENT
[P4–403]: EVALUATION OF RAPID, ON‐SITE APOE GENETIC TESTING FOR SUBJECT OUTREACH AND RECRUITMENT Open
Polymorphisms in the APOE gene have been recognized as the second highest risk factor for Alzheimer's disease after age. For this reason, public awareness and interest in such testing has increased. In our study, three independent memory c…
View article: Targeting Prodromal Alzheimer Disease With Avagacestat
Targeting Prodromal Alzheimer Disease With Avagacestat Open
clinicaltrials.gov Identifier: NCT00890890.